Sun Pharmaceuticals

Sun Pharmaceutical Industries on Sunday revealed in a filing that the firm would see a revenue drop in a few of its businesses and incur some expenses due to an "IT security incident" in March. The drugmaker's IT systems were affected by a breach of certain file systems and theft of some company and personal data, while a ransomware group has claim...

Sun Pharmaceutical Industries Ltd. expects revenue to fall as measures taken by India's top drugmaker to contain an information technology security breach in early March impacted operations.

The import alert means all future shipments of products made at Halol can be refused admission to the US market until the facility becomes compliant with the FDA's Current Good Manufacturing Practice standards,

Drug major Sun Pharmaceutical Industries on Wednesday said its Chairman Israel Makov will retire from the company on August 29, 2022.

Shares of Sun Pharmaceutical Industries fell by over 4 per cent in morning trade on Tuesday a day after the company said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022, mainly on account of a one-time exceptional loss.

Sun Pharmaceutical Industries on Monday said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

Sun Pharmaceutical shares rose as much as 3.51% to hit an intraday high of Rs 703.40 after it signed an agreement with Eli Lilly to make baricitinib.

Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

Pharmaceutical stocks today: On Friday, Cipla opened on the NSE at Rs 840.90, touching an intra day high of Rs 892.30 and an intra day low of Rs 836.65, in the session so far

The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products

Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.

Aquinox Pharmaceuticals is a research and development company focused on pharmaceutical products for the purpose of their commercialisation, Sun Pharma said.

Drug makers around the world are rushing to develop a treatment or vaccine for the fast-spreading novel coronavirus that has killed over 3,90,000 people and ravaged financial markets.

Indian companies are the main supplier of generic drugs to the world and procure almost 70 per centof the active pharmaceutical ingredients (APIs) for their medicines from China. The coronavirus outbreak has disrupted international businesses dependent on Chinese supplies.

Sun Pharmaceutical Industries on Sunday revealed in a filing that the firm would see a revenue drop in a few of its businesses and incur some expenses due to an "IT security incident" in March. The drugmaker's IT systems were affected by a breach of certain file systems and theft of some company and personal data, while a ransomware group has claim...

Sun Pharmaceutical Industries Ltd. expects revenue to fall as measures taken by India's top drugmaker to contain an information technology security breach in early March impacted operations.

The import alert means all future shipments of products made at Halol can be refused admission to the US market until the facility becomes compliant with the FDA's Current Good Manufacturing Practice standards,

Drug major Sun Pharmaceutical Industries on Wednesday said its Chairman Israel Makov will retire from the company on August 29, 2022.

Shares of Sun Pharmaceutical Industries fell by over 4 per cent in morning trade on Tuesday a day after the company said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022, mainly on account of a one-time exceptional loss.

Sun Pharmaceutical Industries on Monday said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

Sun Pharmaceutical shares rose as much as 3.51% to hit an intraday high of Rs 703.40 after it signed an agreement with Eli Lilly to make baricitinib.

Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

Pharmaceutical stocks today: On Friday, Cipla opened on the NSE at Rs 840.90, touching an intra day high of Rs 892.30 and an intra day low of Rs 836.65, in the session so far

The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products

Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.

Aquinox Pharmaceuticals is a research and development company focused on pharmaceutical products for the purpose of their commercialisation, Sun Pharma said.

Drug makers around the world are rushing to develop a treatment or vaccine for the fast-spreading novel coronavirus that has killed over 3,90,000 people and ravaged financial markets.

Indian companies are the main supplier of generic drugs to the world and procure almost 70 per centof the active pharmaceutical ingredients (APIs) for their medicines from China. The coronavirus outbreak has disrupted international businesses dependent on Chinese supplies.